A venture capital firm newly founded in 2023 and dually headquartered in the U.S. and Europe is looking to invest from its new fund in life science startups typically in the Series A round. Typical check size is flexible but ranges from $250k-2M. The firm is looking to invest in companies from the U.S., Europe, Israel, and the Middle East. The firm’s co-founder is NIH trained and has done consulting with the FDA, bringing their expertise to investments and companies.
The firm is investing in life science sectors including: 50% in therapeutics, 20% in medical devices, 20% in diagnostics, and 10% in health-tech. The firm is open to all modalities and technologies. In terms of therapeutics, the firm prefers companies that are Pre-Clinical up to Phase II and will not look farther than that. The firm is indication-agnostic and is open to looking at orphan diseases.
The firm may take a board seat on a case-by-case basis but does not have specific management team requirements. The firm can participate as a lead investor or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Author: Next Phase Admin
Hot Investor Mandate: China-Based Global Pharmaceutical Seeks Innovative Drug Candidates for Strategic Partnership in Oncology, CNS, Autoimmune Disease, and More
One of the leading fully integrated biopharmaceutical companies in China with multiple integrated R&D centers in US and China is actively seeking licensing/collaboration on development candidates with first-in-class or best-in-class potentials and commercial products with substantial market opportunities in China and worldwide.
The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease.
The firm is looking for companies with capacity and experience to implement R&D plans. The firm is interested in incubating companies from scratch.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC Fund Seeks New Opportunities in Digital Health, Software, and Tech-Enabled Healthcare Services
A venture capital fund based in the US looks to make initial equity investments ranging anywhere from $750,000 and up, with most investments falling in the $2-3M million range for the life of the investment. The firm is actively seeking new investments in the US.
The firm is interested in healthcare software companies and tech-enabled healthcare services, with a deep interest in software platforms for clinical trials and pharma services. The firm is interested in B2B SaaS business models and those that have some initial customer traction. The firm is not interested in therapeutics, medical devices, or diagnostics.
The firm does not look to take controlling investments in companies. They take a board seat following investment. The firm is interested in privately held companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Apply before August 9 and Join these Confirmed Companies at RESI September Innovator’s Pitch Challenge (IPC)
By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN
Life Science Nation (LSN)’s next event, RESI September, is coming up on September 18. The conference will take place at the Boston Park Plaza, located in the heart of Boston – a hub of life science and healthcare innovation.
RESI has consistently provided an exceptional opportunity for entrepreneurs to pitch directly to a panel of active investors and industry experts through the Innovator’s Pitch Challenge (IPC). The IPC has rapidly gained popularity and has become the go-to event for many successful entrepreneurs to fine-tune their pitching skills, receive valuable feedback on their products and technologies and connect directly with seasoned investors.
During an IPC session, participating companies will be given 4 minutes for their presentation, followed by 9 minutes of Q&A. IPC’s unique format and judge recruitment process allows companies to pitch alongside fellow entrepreneurs operating in the same sectors and in front of a panel of investor pitch judges who are immensely experienced in that particular sector. By joining the IPC, companies gain not only significant exposure, but also invaluable connections with influential investors and industry experts.
We are excited to announce a selection of the confirmed companies that will be pitching at RESI September. Don’t forget to submit your application before the deadline on August 9 to join these companies at RESI September IPC.
| Confirmed Pitch Companies | ||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
And More… |
Exhibiting at RESI Boston September 2023
By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN
RESI is returning to Boston in September and will be in-person on September 18, with a hybrid digital component on September 19-20. The feedback from exhibitors at our recent conferences has been amazing. The opportunity to engage potential customers from the 300+ early-stage companies that attend RESI, plus the brand visibility, make RESI ideal for service providers catering to these companies, developing technologies in drugs, devices, diagnostics and digital health.
RESI offers different levels of sponsorship to service providers, who can target prospective clients and maximize their brand visibility. Options range from exhibiting at RESI to hosting a sponsored workshop during the conference.
Enhancing Efficiency and Strategy of Investor Outreach
By Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN
Life Science Nation (LSN) has implemented a new pricing model for our Investor and Licensing Partner Database. This database contains 3K+ investor firms, with specific interests in the early-stage life science sector, across 10 categories of investors* and licensing partners, including 10K+ contacts. Searches can be executed through specific filters including but not limited to, sector, subsector, indication, and phase of development. The information presented in the database is obtained directly from each company through 1:1 interviews with investor research analysts at LSN and updated regularly. Â This is a valuable resource for companies looking to establish their Global Target List and execute their fundraising journey.
*10 categories of investors:
|
|
The prior pricing model was $4.5K for 6 months or $7K for 1 year. Since most companies that wish to utilize our database are early-stage and pre-revenue, LSN aimed to transition the hefty up-front cost to a monthly, lower-cost plan. Our new subscription options are shown below:
Standard:
- $300/month or $3K/year up-front
- Minimum 6 months commitment
Premier (Recommended):
- $500/month or $5K/year up-front
- Includes 50% off ALL RESI Registrations for the duration of the subscription (excludes IPC)
- Minimum 6 months commitment
To learn more about this database, please contact your Business Development Manager at Life Science Nation and we would be happy to walk you through the database and help answer any questions or concerns you may have!
|
Life Science Nation Business Development Team
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
 |
 |
 |
|
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Cameron Hurlburt
Manager of Business Development Book a Meeting Email Me |
Hot Investor Mandate: Taiwan VC Invests in Biomaterials, Medical Device, and Digital Health Companies, Open to Cross-Border Investment Opportunities
A venture capital firm in Taipei, Taiwan invests in several sectors including biotechnology, semiconductors, commerce, materials, and software. The firm will invest in companies in Series A and B in Taiwan, Japan, and the U.S. Typical check size ranges from $1-3M USD for early-stage deals. The firm also has an angel fund for Seed stage companies with typical check sizes ranging from $100-3000k USD. Currently, 70% of the firm’s portfolio companies are in Taiwan or Taiwanese-related and 30% are in the U.S. or Japan. The firm has an extended network in the U.S., especially from the Silicon Valley and Boston as most of the founding partners are from Stanford University. If the firm is investing in a Taiwanese company, they tend to lead investments, but for overseas investments, the firm will mostly act as a co-investor.
The firm focuses on biomaterials, medical devices and digital health at in-development or clinical stages. The firm does not invest in pharma or drug development. In terms of medical devices, the firm likes to look at surgery-related devices and for digital health, the firm like to look at software for long-term care. Though, firm is open to all indications and can look at orphan diseases depending on the technology.
The firm focuses on companies that can finalize assets by maximum of 9 years due to the limited fund. The firm may take an observer seat on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 